Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis

References

• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR task force on indirect treatment comparisons good research practices: part 1. Value Health. 2011;14(4):417–428.
   PubMed Web of Science ®Google Scholar
• Schulz KF, Altman DG, Moher D, CONSORT Group, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.
   PubMed Web of Science ®Google Scholar
• The AMCP format for formulary submissions: welcome to version 4.0. J Manag Care Spec Pharm. 2016;22(5):444–446.
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA Draft Guidance. Demonstrating substantial evidence of effectiveness for human drug and biological products: guidance for industry; 2019. Available from: https://www.fda.gov/media/133660/download
   Google Scholar
• European Medicines Agency. ICH Topic E 10: choice of control group in clinical trials. CPMP/ICH/364/96; 2001; [cited 2020 Oct 19]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-10-choice-control-group-clinical-trials-step-5_en.pdf
   Google Scholar
• Cipriani A, Higgins JP, Geddes JR, et al. Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130–137.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Wu EQ, Yu AP, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–945.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Ishak KJ. No head-to-head trial? simulate the missing arms. Pharmacoeconomics. 2010;28(10):957–967.
   PubMed Web of Science ®Google Scholar
• Ishak KJ, Proskorovsky I, Benedict A. Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics. 2015;33(6):537–549.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–211.
   PubMed Web of Science ®Google Scholar
• Phillippo DM, Ades AE, Dias S, et al. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. 2016; [cited 2020 Aug 3]. Available from: http://nicedsu.org.uk/wp-content/uploads/2018/08/Population-adjustment-TSD-FINAL-ref-rerun.pdf
   Google Scholar
• Cope S, Toor K, Popoff E, et al. Critical appraisal of published indirect comparisons and network meta-analyses of competing interventions for multiple myeloma. Value Health. 2020;23(4):441–450.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar
• Diels J, Van Sanden S, Druchok C, et al. Novel evidence synthesis methods to assess comparative efficacy in ‘disconnected’ networks of evidence: a case study assessing comparative efficacy of guselkumab versus interleukin-17 inhibitors for maintenance treatment of moderate-to-severe psoriasis. Poster presented at the annual Fall Clinical Dermatology Conference®; Las Vegas, Nevada, USA; October 2017. p. 12–15.
   Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, FIXTURE Study Group, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–338.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Prinz JC, Gottlieb AB, FEATURE Study Group, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484–493.
   PubMed Web of Science ®Google Scholar
• Paul C, Lacour JP, Tedremets L, JUNCTURE study group, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29(6):1082–1090.
   PubMed Web of Science ®Google Scholar
• Lacour JP, Paul C, Jazayeri S, et al. Secukinumab administration by autoinjector maintains reduction of plaque psoriasis severity over 52 weeks: results of the randomized controlled JUNCTURE trial. J Eur Acad Dermatol Venereol. 2017;31(5):847–856.
   PubMed Web of Science ®Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551.
   PubMed Web of Science ®Google Scholar
• Diels J, Thilakarathne P, Van Sanden S, et al. Three-year clinical efficacy of guselkumab and ixekizumab in moderate-to-severe plaque psoriasis: a matching-adjusted indirect comparison. Poster presented at the annual Fall Clinical Dermatology Conference®; 17–20 October 2019; Las Vegas, Nevada, USA; 2019.
   Google Scholar
• Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936–945.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824–830.e2.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831–839.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp K, Gottlieb A, IXORA-R Study Group, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–1358.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Pinter A, Tada Y, et al. Ixekizumab versus guselkumab: 24-week clinical responses and 4-week gene expression data. Poster LB940. Presented at the 2020 Society for Investigative Dermatology (SID) Annual Meeting Virtual Conference; May 13–16; Scottsdale, Arizona, USA; 2020.
   Google Scholar
• Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Papp KA, Lynde CW. Shifting the focus – the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol. 2018;32(7):1111–1119.
   PubMed Web of Science ®Google Scholar
• Pocock SJ. The combination of randomized and historical controls in clinical trials. J Chronic Dis. 1976;29(3):175–188.
   PubMedGoogle Scholar
• Sawyer LM, Malottki K, Sabry-Grant C, et al. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. PLOS One. 2019;14(8):e0220868.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Saure D, Wilhelm S, et al. Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12. J Dermatolog Treat. 2020;33(1):54–61.
   PubMed Web of Science ®Google Scholar
• Song F, Altman DG, Glenny A-M, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ. 2003;326(7387):472–472.
   PubMed Web of Science ®Google Scholar
• Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009;338(apr03 1):b1147.
   PubMedGoogle Scholar